Cumberland Pharmaceuticals vs Tonix Pharmaceuticals
CPIX and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CPIX and TNXP compare
Cumberland Pharmaceuticals is the larger company, worth 1.4 times as much as Tonix Pharmaceuticals ($91.7M against $66.4M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus −1.1% for Cumberland Pharmaceuticals).
Cumberland Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −34.9% compared with −420% at Tonix Pharmaceuticals.
Cumberland Pharmaceuticals pays a dividend yielding 24.5%; Tonix Pharmaceuticals does not pay one.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 5 for Cumberland Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CPIX | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $91.7M | $66.4M |
| Share price | $6.12 | $3.87 |
| Change, 1 year | 209% | −77.0% |
| Change, 5 years | 146% | −100.0% |
| Beta (5Y) | 0.29 | 2.06 |
| Employees | 93 | 142 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/S | 2.9× | 1.5× (better) |
| P/B | 5.3× | 0.3× (better) |
| P/FCF | 134× | – |
| FCF yield | 0.75% (better) | −256% |
| Fair value | $3.52 | $18.90 |
| Margin of safety | −73.8% | 79.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −1.1% | 318% (better) |
| Revenue growth, 5Y average | 3.5% | – |
| Profitability | ||
| Gross margin | – | 89.3% |
| Operating margin | −30.8% (better) | −436% |
| Net margin | −34.9% (better) | −420% |
| FCF margin | 2.2% (better) | −395% |
| Return on equity | −48.1% (better) | −84.1% |
| Return on invested capital | −59.7% (better) | −388% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −31.1× | – |
| Current ratio | 0.96 | 4.57 (better) |
| Altman Z-score | 0.40 (better) | −6.42 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 24.5% | – |
| Buyback yield | 0.08% (better) | −224% |
| Shareholder yield | 24.6% (better) | −224% |
| Ownership | ||
| Held by institutions | 16.5% | 54.6% |
| Held by insiders | 80.2% | 0.24% |
| Insider net buying, 12 months | – | $459K |
| Short interest, % of float | 10.1% | 19.4% |
Go deeper
- CPIX stock overview
- CPIX income statement
- CPIX valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.